Personalis Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Personalis stock.
View analyst ratings for Personalis or view top-rated stocks.

Wall Street analysts have given Personalis a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Personalis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Personalis is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Personalis.

Personalis, Inc. (NASDAQ:PSNL) released its quarterly earnings results on Wednesday, May, 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.08. Personalis had a negative trailing twelve-month return on equity of 21.21% and a negative net margin of 55.43%.
View Personalis' earnings history.

Personalis' stock was trading at $6.02 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PSNL stock has increased by 278.7% and is now trading at $22.80.
View which stocks have been most impacted by COVID-19.

Personalis updated its second quarter 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $21.30 million-$21.30 million, compared to the consensus revenue estimate of $21.23 million.

9 brokerages have issued 1 year target prices for Personalis' stock. Their forecasts range from $28.00 to $50.00. On average, they expect Personalis' share price to reach $37.78 in the next year. This suggests a possible upside of 65.7% from the stock's current price.
View analysts' price targets for Personalis or view top-rated stocks among Wall Street analysts.

17 employees have rated Personalis CEO John West on Glassdoor.com. John West has an approval rating of 75% among Personalis' employees.

Some companies that are related to Personalis include Burning Rock Biotech (BNR), Veracyte (VCYT), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Genetron (GTH), RadNet (RDNT), DermTech (DMTK), Renalytix AI (RNLX), Celcuity (CELC), Exagen (XGN), Centogene (CNTG), Enzo Biochem (ENZ), Progenity (PROG), Vyant Bio (VYNT) and OpGen (OPGN).
View all of PSNL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Enphase Energy (ENPH), Pfizer (PFE), Dynavax Technologies (DVAX), QUALCOMM (QCOM), Advanced Micro Devices (AMD), NIO (NIO), NVIDIA (NVDA), Viking Therapeutics (VKTX), AbbVie (ABBV) and (APHA).

(PSNL) raised $100 million in an IPO on Thursday, June 20th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager.

Personalis trades on the NASDAQ under the ticker symbol "PSNL."

Personalis' stock is owned by many different retail and institutional investors. Top institutional investors include ARK Investment Management LLC (12.99%), JPMorgan Chase & Co. (8.28%), BlackRock Inc. (5.95%), Sumitomo Mitsui Trust Holdings Inc. (2.79%), Nikko Asset Management Americas Inc. (2.79%) and Wellington Shields Capital Management LLC (2.07%). Company insiders that own Personalis stock include Aaron Tachibana, John Stephen West, Ken Ludlum, Lightspeed Venture Partners Se, Llp Abingworth and Richard Chen.
View institutional ownership trends for Personalis.

PSNL stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Alyeska Investment Group L.P., Parian Global Management LP, Bank of Montreal Can, HRT Financial LP, Jane Street Group LLC, Ameriprise Financial Inc., and Citigroup Inc.. Company insiders that have sold Personalis company stock in the last year include Aaron Tachibana, John Stephen West, Ken Ludlum, Llp Abingworth, and Richard Chen.
View insider buying and selling activity for Personalis or view top insider-selling stocks.

PSNL stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Dimensional Fund Advisors LP, JPMorgan Chase & Co., BlackRock Inc., Voloridge Investment Management LLC, Pacific Heights Asset Management LLC, Tekla Capital Management LLC, and Morgan Stanley. Company insiders that have bought Personalis stock in the last two years include Ken Ludlum, and Lightspeed Venture Partners Se.
View insider buying and selling activity for Personalis or or view top insider-buying stocks.

Shares of PSNL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PSNL stock can currently be purchased for approximately $22.80.

Personalis has a market capitalization of $1.00 billion and generates $78.65 million in revenue each year. The company earns $-41,280,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.

Personalis employs 234 workers across the globe.

The official website for Personalis is www.personalis.com.

Personalis is headquartered at 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025.

Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company can be reached via phone at 650-752-1300 or via email at [email protected]